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ABSTRACT
Objective: To assess bone turnover markers (BTM) and bone mineral density (BMD) after 
discontinuation of alendronate treatment used for five or more years. Subjects and me-
thods: 40 patients (pt) with post-menopausal osteoporosis treated with alendronate (10 
mg/d) for at least five years (Group 1, G1) had their medication discontinued. Group 2 
(G2): 25 pt treated with alendronate for at least one year. Group 3 (G3): 23 treatment-naïve 
osteoporotic pt. BMD was evaluated in G1 and G2 at baseline and after 12 months. Colla-
gen type I cross-linked C-telopeptide (CTX) and procollagen type 1 N-terminal propeptide (P1NP) 
levels were measured in all pt at baseline, and in G1 and G2 every three months for 12 
months. Data were analyzed using ANOVA on ranks and Mann-Whitney tests. Results: 
Mean BMD values in G1 and G2 did not differ during follow-up. However, 16 pt (45.7%) in 
G1 and one (5.2%) in G2 lost BMD (P < 0.001). BTM at baseline was not different between 
G1 and G2, and both were lower than G3. A significant increase in BTM levels was detec-
ted in G1 pt after three months, but not in G2. Conclusion: Observed BMD loss and BTM 
rise after alendronate withdrawal imply that bone turnover was not over suppressed, and 
alendronate discontinuation may not be safe. Arq Bras Endocrinol Metab. 2011;55(4):272-8
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RESUMO
Objetivo: Avaliar a evolução dos marcadores de metabolismo ósseo (MMO) e da densidade mi-
neral óssea (DMO) após cinco anos de uso de alendronato em mulheres osteoporóticas na pós-
-menopausa. Sujeitos e métodos: 40 pacientes (pct) osteoporóticas, na pós-menopausa, em 
uso de alendronato (10 mg/dia) por pelo menos 5 anos (Grupo 1 − G1) tiveram o uso do 
bisfosfonato suspenso. O grupo 2 (G2): 25 mulheres na pós-menopausa, em uso de alen-
dronato (10 mg/dia) há pelo menos 1 ano. Grupo 3 (G3): 23 pct osteoporóticas, controles 
ainda sem tratamento. G1 e G2 submeteram-se à avaliação da DMO por DXA (basal e após 
12 meses de seguimento). Todas as pct colheram amostras basais de CTX e P1NP, e G1 e 
G2 submeteram-se a coletas trimestrais de CTX e P1NP durante 1 ano. Resultados foram 
analisados por ANOVA on ranks e Mann-Whitney. Resultados: Níveis médios de DMO não 
variaram em G1 ou G2 durante o estudo; no entanto, 16 pct (45,7%) no G1 e 1 pct (5,2%) no 
G2 apresentaram redução clinicamente significativa de DMO (P < 0,001). Níveis basais de 
CTX e P1NP não diferiram entre G1 e G2, com ambos inferiores aos níveis de G3. Em G1, 
observou-se elevação significativa de CTX e P1NP após 3 meses. Os níveis de CTX e P1NP 
em G2 permaneceram estáveis durante todo o seguimento. Conclusão: Não parece haver 
supressão excessiva do metabolismo ósseo na prática clínica. A suspensão temporária do 
alendronato após seu uso prolongado pode não ser segura. Arq Bras Endocrinol Metab. 2011;55(4):272-8
Descritores
Marcadores de metabolismo ósseo; densidade mineral óssea; alendronato; osteoporose 
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INTRODUCTION
Postmenopausal osteoporosis (PMO) is a chronic, progressive disorder in which bone resorption ex-
ceeds formation, resulting in a net decrease of bone 
mass and impairment of microarchitecture. The wide 
clinical spectrum of osteoporosis ranges from asymp-
tomatic bone loss to disabling fractures that increase 
the public health care burden worldwide (1). Bisphos-
phonates are the most commonly prescribed drugs for 
the treatment of osteoporosis, with multiple clinical tri-
als documenting a reduction in the incidence of verte-
bral, non-spinal, and hip fractures in older women at 
moderate to high risk (2). These drugs are analogues 
of inorganic pyrophosphate and have a unique mecha-
nism of action in which they tightly adhere to bone sur-
faces, especially where bone resorption is more intense. 
They are then slowly released as bone is resorbed by 
osteoclasts, blocking signals that organize the ruffled 
border and inhibiting bone resorption by these cells 
(3). Alendronate sodium is one of the most potent oral 
bisphosphonates. This drug has been shown to increase 
bone mass density and reduce the risk of fracture when 
used continuously for long periods; published data has 
shown sustained therapeutic effects on bone density 
and remodeling for up to ten years of use (4). 
Pharmacokinetic studies show that bisphosphonates 
persist in bone matrix for many years, and incorpora-
ted bisphosphonate molecules remain inactive, until 
the bone containing them is resorbed. The half-life of 
alendronate is similar to that of bone mineral, approxi-
mately ten years (5). Thus, skeletal effects of alendro-
nate and other bisphosphonates may persist for long 
periods after discontinuation of the treatment. This has 
led some practitioners to suggest a “drug holiday”, or 
a temporary discontinuation of the drug, during which 
patients would still be protected from increased bone 
turnover and fractures (6). However, data on the evo-
lution of bone turnover shortly after discontinuation 
are lacking. Some studies have demonstrated an increa-
se in bone turnover markers approximately one year af-
ter discontinuation (4,5), but the relationship between 
this observation and a possible increase in fracture rate 
is unclear. Indeed, a recent randomized controlled trial 
of 1099 women who received alendronate for a mean 
of five years found similar risks of fracture for the follo-
wing five years among patients who were randomly swi-
tched to placebo versus continued treatment (5). Other 
trials with long-lasting use of alendronate (4) and rise-
dronate (7) did not show higher risk of severe adverse 
effects, either.
Despite these data, the antiresorptive properties and 
long half-life of bisphosphonates have generated theo-
retical concern about possible over suppression of bone 
turnover, since the first studies using alendronate (8). 
Odvina and cols. (9) reported nine cases of sustained, 
spontaneous, non-spinal fractures while on alendronate 
long-term therapy, six of whom displayed either delayed 
or absent fracture healing, from three months to two ye-
ars during therapy. Concerns related to a higher risk of 
non-healing lesions in the jaw of patients receiving high-
-dose intravenous bisphosphonate therapy (10) offer 
another reason for which at least temporary drug discon-
tinuation might be a desirable option after years of use. 
The aim of the study was to assess the effects of 
a 12-month discontinuation of alendronate on bone 
turnover markers (BTM) and bone mineral density 
(BMD) in postmenopausal osteoporotic patients on 
long-term (at least 5 years) alendronate therapy in a 
bone metabolism unit.
METHODS
Subjects
From April 2006 to June 2007, 42 consecutive post-
menopausal women (age 71.0 ± 6.7 years old) on 
continuous alendronate therapy for at least five years 
(10 mg/day, regularly provided by the Brazilian go-
vernment) in our practice were invited to participate in 
the study, during their follow-up appointments in the 
bone metabolism unit. Forty of these patients agreed to 
participate, and formed group 1 (G1). All of them were 
submitted to discontinuation of alendronate treatment 
at baseline, and had follow-up appointments for one 
year. Women with low calcium intake received supple-
mentation in a dose sufficient to achieve 1000 mg/day. 
All patients received cholecalciferol (1000 IU/day) du-
ring this period. Simultaneously, 25 consecutive osteo-
porotic patients, paired by age (70.6 ± 6.9 years old), 
who had used alendronate regularly for at least one year 
and no more than four years, were recruited and made 
up group 2 (G2). These patients continued to use bis-
phosphonate during the follow-up period, and follo-
wed the same protocol of G1 regarding calcium and 
cholecalciferol supplementation. Group 3 (G3; con-
trols) consisted of 23 age-paired (70.0 ± 6.8 years old), 
recently-diagnosed and untreated, post-menopausal 
osteoporotic patients. All patients provided written in-
formed consent, and the protocol was approved by the 
ethics committee of the institution.
Discontinuing long-term alendronate therapy
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Table 1. Baseline characteristics of study subjects
Baseline 
characteristics
G1  
(n = 40)
G2  
(n = 25)
G3  
(n = 23) P*
Age (years) 71 ± 6.7 y 70.6 ± 6.9 y 70 ± 6.8 y NS
Body mass index (kg/m2) 24.7 ± 3.1 24.8 ± 3.4 25.4 ± 3.7 NS
Race White 34 21 18 NS
Asian 4 2 3 NS
Black 2 2 2 NS
Tobacco 
user
Previous 9 6 6 NS
Current 4 2 1 NS
Never 27 17 18 NS
Fractures 9 5 3 NS
* NS: non significant.
Design
To follow bone turnover in patients still on alendro-
nate treatment (G2) and in patients who had discon-
tinued alendronate (G1), fasting blood samples were 
collected at baseline and every three months for one 
year to measure bone resorption marker collagen type 
I cross-linked C-telopeptide (CTX) and the bone for-
mation marker procollagen type 1 N-terminal pro-
peptide (P1NP). All samples were collected in the 
early morning and immediately analyzed or stored at 
-20°C until analysis. To follow variations in vitamin 
D status that could interfere with the results, we also 
measured 25-hydroxy-vitamin D (25OHD) levels in 
G1 patients at baseline and after 12 months. Para-
thyroid hormone (PTH) and ionized calcium were 
determined in G1 and G2 patients at baseline and 
after six and 12 months. To provide reference values 
for untreated osteoporotic patients of similar age, 
baseline samples for CTX and P1NP were collected 
from G3 patients.
BMD of the lumbar spine and proximal femur were 
measured by dual-energy x-ray absorptiometry (DXA; 
DPX-L, Lunar, USA) in 35 patients of G1 and 19 pa-
tients of G2 at baseline and at the end of the follow-up 
period. The coefficient of variation (CV %) of DXA me-
asured in vivo was 1.0% for the lumbar spine and 1.5% 
for the proximal femur.
Laboratory evaluation
Both BTM and BMD were measured using commer-
cial kits (Chemoluminescence, Elecsys analyzers; Roche 
Diagnostic, Indianapolis, IN, USA). For CTX, intra-
-assay CV% was 4.6%, and inter-assay CV% was 4.7%. 
For P1NP, intra-assay CV% was 1.7%, and inter-assay 
CV% was 2.7%. Evaluation of 25-hydroxy-vitamin D 
(25OHD) was carried out by a commercial kit (Nichols 
Institute Diagnostics, CA, USA) based on chemolumi-
nescence (intra-assay CV% was 16.5%; inter-assay CV% 
was 9.7%). Reference values were obtained from the li-
terature. Intact PTH was analyzed by means of an in-
-house immunofluorometric assay, with reference value 
of 10 to 70 pg/mL (11). Ionized calcium was assessed 
by an automatic electrolyte analyzer (AVL 984-S, Min-
nesota, USA), with a normal values of 1.20 to 1.40 mM.
Statistical analysis 
All participants in groups 1 and 2 were included in the 
analysis. We compared the mean percent change from 
baseline in lumbar spine and proximal femur BMD se-
parately for each group, using paired t tests. Only BMD 
losses of at least 2.8% in lumbar spine and 4.2% in femur 
were considered clinically significant (according to the 
ISCD recommendations for our device) (12). Based on 
these criteria, we compared incidences of bone loss be-
tween baseline and after one year of follow-up using the 
chi-square test. All values are presented as mean ± stan-
dard deviation (SD). Baseline and final 25OHD levels 
in G1 were compared using paired t test. Within-group 
variation in bone turnover markers, PTH and calcium 
levels during the follow-up period were analyzed using 
ANOVA on ranks; results were transformed in log va-
lues when appropriate. Spearman rank correlation co-
efficient was used to compare cumulative BMD varia-
tion in G1 and G2 with CTX and P1NP variation, and 
vitamin D, PTH and calcium status. All analyses were 
conducted in SPSS 16.0 software (SPSS Inc., USA) and 
StatView 5.0 software (SAS institute Inc., USA).
RESULTS
Baseline characteristics of patients who were using or 
had previously used alendronate are displayed in table 1. 
Although BMD levels were higher in G1 compared with 
G2 patients at baseline and after one year, we did not 
observe any statistically significant difference between 
mean BMD levels at baseline, or after one year of follow-
-up in either group. During follow-up, however, 45.7% 
of G1 patients clinically lost BMD in the lumbar spine, 
femoral neck or both. Among patients still taking the 
drug (G2), we observed BMD loss in only one (5.2%, 
Table 2). Only one G1 patient reported a wrist fracture 
after high-energy trauma during the study. There were 
no reported fractures in G2 during this period. 
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Table 2. BMD at baseline and after 1 year of discontinuation of alendronate in G1, and during follow-up in G2
Group BMD (g/cm2) Baseline 1 Year P Lost BMD
G1 (n = 35) Spine 0.868 ± 0.142* 0.858 ± 0.134* 0.85 14 (40%)**
Femoral neck 0.724 ± 0.099* 0.730 ± 0.101* 0.86 10 (28%)**
G2 (N = 19) Spine 0.790 ± 0.192 0.798 ± 0.211 0.89 1 (5.2%) 
Femoral neck 0.670 ± 0.112 0.656 ± 0.102 0.66 1 (5.2%) 
* P: 0.01 vs. G2. ** P < 0.001 vs. G2.
Lost BMD: patients with clinically significant BMD loss (at least 2.8% in spine or 4.2% in hip, or both).
Table 3. PTH and calcium levels during follow-up in G1 and G2
Group
PTH (pg/ml) Ionized calcium (nmol/L)
P
Baseline 6 mo 9 mo Baseline 6 mo 9 mo
G1 50.6 ± 28.5 45.0 ± 26.4  36.0 ± 18.7 1.29 ± 0.04 1.30 ± 0.05 1.28 ± 0.04 NS
G2 48.1 ± 19.0 43.36 ± 18.7  39.6 ± 16.1  1.27 ± 0.05  1.28 ± 0.04  1.27 ± 0.05 NS
Values for bone turnover markers in G1, G2 and G3 
patients during follow-up are displayed in Figures 1 (CTX) 
and 2 (P1NP). During the study, G1 patients presented a 
significant elevation in CTX levels compared with baseline 
after three months of follow-up. Compared with 3-month 
levels, we did not observe any additional statistically signi-
ficant elevation in CTX levels after 6, 9 or 12 months of 
follow-up; even after one year, CTX values were still sig-
nificantly lower than control levels (G3). Bone formation 
marker P1NP showed a similar elevation in G1 patients 
after three months of follow-up. We observed continuous 
elevation in P1NP levels after 6, 9 and 12 months, with 
P1NP levels equivalent to those of G3 patients after nine 
months. In G2 patients, CTX and P1NP levels were stable 
and similar to baseline throughout the follow-up period, 
and were also lower than in untreated controls.
Mean PTH levels in G1 and G2 patients remained 
close to baseline during follow-up (Table 3). A similar 
pattern, with no statistically significant difference from 
baseline, was observed for ionized calcium levels in G1 
and G2 (Table 3). Similarly, 25OHD levels (ng/mL) in 
G1 patients remained stable after one year of follow-up 
(28.1 ± 12.1 and 27.3 ± 8.4, respectively; P = nonsig-
nificant).
We did not find any significant correlation betwe-
en BMD variation and CTX, P1NP, PTH, calcium or 
25OHD levels during the study. There was no statis-
tically significant difference between the group with 
or without clinically significant BMD loss and baseline 
CTX and P1NP levels, and no difference was observed 
between CTX or P1NP levels during the follow-up pe-
riod and prevalence of BMD loss, either.
Figure 1. CTX levels during the follow-up period in G1 and G2, and baseline G3 levels. 
9 mo
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Figure 2. P1NP levels during the follow-up period in G1 and G2, and baseline G3 levels. 
DISCUSSION
Bisphosphonates increase BMD by slowing bone turno-
ver and allowing secondary mineralization to progress, 
which in turn leads to increased bone mineral content 
(11). By inhibiting osteoclast action (and therefore 
bone resorption), bisphosphonates, such as alendro-
nate, act reducing BTM levels and increasing BMD. 
Although changes in BMD and BTM cannot entirely 
explain observed fracture risk reduction with alendrona-
te therapy (13,14), these are the most important predic-
tors of fracture risk in clinical practice, and the most ea-
sily measurable surrogates for treatment-related efficacy 
in osteoporosis. Considering the potential for residual 
effects of alendronate after discontinuation, as well as 
the possibility of offering “drug holidays”, periodic me-
asurements of BMD and BTM after discontinuation of 
long-term alendronate therapy could be useful tools in 
monitoring the persistence of the anti-resorptive effect. 
In our study, higher BMD levels were observed in 
G1 compared with G2 patients, probably reflecting 
the longer period of treatment in the former group. 
Although mean BMD was similar to baseline at the end 
of the study in G1 and G2, BMD decreased by a cli-
nically significant amount in 45.7% of patients in the 
first year of treatment, but only in 5.2% of the patients 
in continuous treatment. Bone resorption markers in 
G1 patients increased during the follow-up period, but 
remained lower than in the control group even after 
one year, suggesting partial resolution of effect. Bone 
formation markers, on the other hand, did return to 
control levels and thus showed complete resolution 
of effect. This last result is more difficult to interpret. 
Our data agree with other studies that have sugges-
ted that persistent inhibition of bone resorption oc-
curs for perhaps a few years when alendronate therapy 
(~10 mg/d) is discontinued (15) (16). The response 
to discontinuation of alendronate treatment is clearly 
distinct from the rapid increase in bone turnover when 
estrogen therapy is discontinued (15). Similar respon-
ses were observed after discontinuing risedronate (13). 
At one-year of follow-up, 25OHD levels in G1 
patients were not significantly different from baseli-
ne. Because there is a significant seasonal variation in 
25OHD levels at higher latitudes, closely related to se-
asonal ultraviolet (UV)-B radiation levels (17), signifi-
cant variations in 25OHD levels could be missed with 
yearly measurements. Our group studied the influen-
ce of UV radiation on the production of 25OHD in 
the elderly population of the same city of the present 
study (18), and found a seasonal variation in 25OHD 
levels that strongly correlated with PTH levels when 
separated into the seasons of the year. Secondary hyper-
parathyroidism, determined by high PTH serum con-
centrations and normal calcemia, occurred in 35.7% of 
patients in summer and 70% in winter. 
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Despite these data, we did not observe any signifi-
cant variation in serum calcium or PTH levels in G1 or 
G2 patients during follow-up. All G1 and G2 patients 
persisted in the use of vitamin D (1,000 IU/day) and 
calcium (when daily intake was below 1,000 mg/day) 
during the observation period. Daily supplementation 
with 800-1000 IU/day of vitamin D was able to ele-
vate 25OHD levels in other studies, preventing vita-
min D deficiency and secondary hyperparathyroidism 
(19). These data, in addition to the observed stability 
of BTM in G2 patients during follow-up, minimize the 
possibility of significant bone turnover variation in our 
patients, or seasonality of our results. 
Because calcium and vitamin D can suppress BTM 
and maximize the response to bisphosphonates (11), 
such supplementation could be responsible for the 
persistent bone turnover suppression observed after 
discontinuation of bisphosphonate in G1 patients. In 
a systematic review of the literature, Bischoff-Ferrari 
and cols. (20) showed that, relative to calcium alone 
or placebo, vitamin D supplementation (700 to 800 
IU/day) reduced the relative risk (RR) of hip fracture 
by 26% (95% confidence interval - CI, 0.61 – 0.88), 
and that of any non-vertebral fracture by 23% (95% CI, 
0.68 – 0.87). However, no matter the dose of vitamin 
D, the decline in BMD following discontinuation of 
alendronate was, in other studies, lower than that seen 
after discontinuation of estrogen (15), raloxifene (21), 
or intermittent parathyroid hormone (22). Similarly, 
gradual BTM elevation observed in our study after dis-
continuation of alendronate contrasts with the sharp 
and immediate gains usually seen following estrogen, 
raloxifene or parathyroid hormone discontinuation (5), 
suggesting a residual effect of alendronate. 
 As mentioned above, our study has successfully de-
monstrated that prolonged alendronate exposure leads 
to persistence of decreased bone turnover after discon-
tinuation, even at one-year follow-up. Decreased bone 
turnover has been associated with decreased fracture 
risk, independent of the effects on BMD (5). Potential 
mechanisms include a reduction in the depth and size 
of new resorption sites, and a deceleration of the remo-
deling cycle, which would enhance the effectiveness of 
the secondary mineralization of the bone matrix and 
potentially stabilize trabecular microarchitecture (23). 
Conversely, controversial data have been reported on 
the effect of long-term reduction of bone turnover on 
bone health: some experimental data suggest that redu-
ced turnover may decrease bone strength by allowing 
accumulation of microcracks, thereby increasing bone 
brittleness (24). However, other studies indicate that 
such accumulation could be beneficial (25). Evidence 
from most studies to date indicates a decreased risk of 
vertebral fractures after long-term use of alendronate, 
with low related morbidity; continuous use of alendro-
nate for longer periods, therefore, does not seem to 
have a deleterious impact on bone strength. 
Bone remodeling is not completely suppressed with 
the usual doses of alendronate. Additional suppression 
of bone turnover can be observed when estrogen the-
rapy is added to the treatment (15). Clinical states of 
low bone remodeling, such as hypoparathyroidism, 
have not been associated with untoward skeletal defects 
(26). Studies reporting the 7-year experience with ri-
sedronate (7) and 10-year experience with alendronate 
(4) corroborate those data, suggesting that long-term 
treatment with these agents may be quite safe, with low 
risk of adverse effects associated with the usual doses.
If long-term alendronate treatment for osteoporo-
sis is indeed safe, given the lack of clear evidence of 
over suppression in our patients, after discontinuation 
of long-term continuous alendronate therapy, perhaps 
the most important issue about prolonged antiresorp-
tive treatment for osteoporosis is whether it is really 
necessary or safe to offer a drug holiday to patients who 
have taken these drugs for many years. Some authors 
suggest that it might be reasonably safe, with respect to 
the risk of hip fracture, to take a holiday of at least one 
year (6), and others have reported that discontinuation 
did not increase the risk of non-vertebral fractures or 
x-ray-detected vertebral fractures after five years (5). 
However, the clinically significant decrease in BMD 
observed in 45.7% of our patients after discontinuation 
of alendronate raises some concerns, even without an 
associated increase in fractures during this period. It 
may be advisable for patients with risk factors for osteo-
porotic fractures, including low weight, frailty, smoking 
and personal and familiar history of fractures, to avoid 
drug discontinuation, persisting in the use of bisphos-
phonates for longer periods. 
Our study has limitations. The short period of 
follow-up did not enable the evaluation of risk of frac-
tures after discontinuation of alendronate. Much of the 
value of our study lies in its design: by including all the 
patients in our practice who fit the inclusion criteria, 
our study simulated what happens in “real life” (gene-
ral practice), outside the limits of randomized, clinical 
trials. The study design allowed us to answer questions 
Discontinuing long-term alendronate therapy
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commonly encountered in daily clinical practice, e.g., 
whether a “drug holiday” should really be offered to 
osteoporotic patients after long-term bisphosphonate 
therapy, as well as the safety of that decision. 
In conclusion, these findings support the sustai-
ned use of alendronate for at least five years without 
clinical evidence of bone turnover over suppression 
in postmenopausal patients, confirming the safety of 
prolonged use of this drug. There were no statisti-
cally significant variations in bone turnover markers 
or BMD levels in patients still using alendronate; ho-
wever, the elevated percentage of patients who had 
clinically significant bone loss after discontinuing 
alendronate generates concern about the safety of 
even temporary discontinuation of antiresorptive tre-
atment for osteoporosis, especially in patients at a hi-
gher risk of fracture. 
Acknowledgements and conflict of interest disclosure: Marise 
Lazaretti-Castro is consultant from Sanofi-Aventis and Novartis, 
and participates as principal investigator in clinical research trials 
supported by Merck, Sharp & Dohme, Eli Lilly and Pfizer. CTX 
and P1NP kits were kindly provided by Roche Diagnósticos. 
There are no more potential conflicts of interest. 
REFERENCES
1. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-
-Connor E, Musliner TA, et al. Effect of alendronate on risk of 
fracture in women with low bone density but without vertebral 
fractures: results from the Fracture Intervention Trial. JAMA. 
1998;280(24):2077-82.
2. Bilezikian JP. Efficacy of bisphosphonates in reducing fracture 
risk in postmenopausal osteoporosis. Am J Med. 2009;122(2 
Suppl):S14-21.
3. Strewler GJ. Decimal point--osteoporosis therapy at the 10-year 
mark. N Engl J Med. 2004;350(12):1172-4.
4. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino 
RP, et al. Ten years’ experience with alendronate for osteoporosis 
in postmenopausal women. N Engl J Med. 2004;350(12):1189-99.
5. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt 
SA, et al. Effects of continuing or stopping alendronate after 5 
years of treatment: the Fracture Intervention Trial Long-term Ex-
tension (FLEX): a randomized trial. JAMA. 2006;296(24):2927-38.
6. Curtis JR, Westfall AO, Cheng H, Delzell E, Saag KG. Risk of hip 
fracture after bisphosphonate discontinuation: implications for a 
drug holiday. Osteoporos Int. 2008;19(11):1613-20.
7. Mellstrom DD, Sörensen OH, Goemaere S, Roux C, Johnson 
TD, Chines AA. Seven years of treatment with risedronate in 
women with postmenopausal osteoporosis. Calcif Tissue Int. 
2004;75(6):462-8.
8. Chesnut CH 3rd, McClung MR, Ensrud KE, Bell NH, Genant HK, 
Harris ST, et al. Alendronate treatment of the postmenopausal os-
teoporotic woman: effect of multiple dosages on bone mass and 
bone remodeling. Am J Med. 1995;99(2):144-52.
9. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. 
Severely suppressed bone turnover: a potential complication of 
alendronate therapy. J Clin Endocrinol Metab. 2005;90(3):1294-301.
10. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: 
bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 
2006;144(10):753-61.
11. Deane A, Constancio L, Fogelman I, Hampson G. The impact of 
vitamin D status on changes in bone mineral density during treat-
ment with bisphosphonates and after discontinuation following 
long-term use in post-menopausal osteoporosis. BMC Muscu-
loskelet Disord. 2007;8:3.
12. Lewiecki EM, Gordon CM, Baim S, Leonard MB, Bishop NJ, Bian-
chi ML, et al. International Society for Clinical Densitometry 2007 
Adult and Pediatric Official Positions. Bone. 2008;43(6):1115-21.
13. Watts NB, Chines A, Olszynski WP, McKeever CD, McClung MR, 
Zhou X, et al. Fracture risk remains reduced one year after discon-
tinuation of risedronate. Osteoporos Int. 2008;19(3):365-72.
14. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix 
AZ, et al. Improvement in spine bone density and reduction in 
risk of vertebral fractures during treatment with antiresorptive 
drugs. Am J Med. 2002;112(4):281-9.
15. Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, 
et al. Significant differential effects of alendronate, estrogen, or com-
bination therapy on the rate of bone loss after discontinuation of 
treatment of postmenopausal osteoporosis. A randomized, double-
-blind, placebo-controlled trial. Ann Intern Med. 2002;137(11):875-83.
16. Ravn P, Weiss SR, Rodriguez-Portales JA, McClung MR, Wasnich 
RD, Gilchrist NL, et al. Alendronate in early postmenopausal wo-
men: effects on bone mass during long-term treatment and after 
withdrawal. Alendronate Osteoporosis Prevention Study Group. 
J Clin Endocrinol Metab. 2000;85(4):1492-7.
17. Lucas JA, Bolland MJ, Grey AB, Ames RW, Mason BH, Horne AM, 
et al. Determinants of vitamin D status in older women living in a 
subtropical climate. Osteoporos Int. 2005;16(12):1641-8.
18. Saraiva GL, Cendoroglo MS, Ramos LR, Araújo LM, Vieira JG, Ku-
nii I, et al. Influence of ultraviolet radiation on the production of 25 
hydroxyvitamin D in the elderly population in the city of Sao Paulo 
(23 degrees 34’S), Brazil. Osteoporos Int. 2005;16(12):1649-54.
19. Dawson-Hughes B, Bischoff-Ferrari HA. Therapy of osteoporosis 
with calcium and vitamin D. J Bone Miner Res. 2007;22 Suppl 
2:V59-63.
20. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietri-
ch T, Dawson-Hughes B. Fracture prevention with vitamin D su-
pplementation: a meta-analysis of randomized controlled trials. 
JAMA. 2005;293(18):2257-64.
21. Neele SJ, Evertz R, De Valk-De Roo G, Roos JC, Netelenbos JC. 
Effect of 1 year of discontinuation of raloxifene or estrogen thera-
py on bone mineral density after 5 years of treatment in healthy 
postmenopausal women. Bone. 2002;30(4):599-603.
22. Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, 
et al. One year of alendronate after one year of parathyroid hor-
mone (1-84) for osteoporosis. N Engl J Med. 2005;353(6):555-65.
23. Rosen CJ. Clinical practice. Postmenopausal osteoporosis. N 
Engl J Med. 2005;353(6):595-603.
24. Burr DB. Targeted and nontargeted remodeling. Bone. 2002;30(1):2-4.
25. Roschger P, Rinnerthaler S, Yates J, Rodan GA, Fratzl P, Klaushofer K. 
Alendronate increases degree and uniformity of mineralization 
in cancellous bone and decreases the porosity in cortical bone of 
osteoporotic women. Bone. 2001;29(2):185-91.
26. Shukla ST, Gillespy 3rd, Thomas WC Jr., The effect of hypo-
parathyroidism on the aging skeleton. J Am Geriatr Soc. 
1990;38(8):884-8.
Discontinuing long-term alendronate therapy
